[1] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology,2014,60:715-735.
[2] Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol, 2011,54:640-649.
[3] Wright G, Noiret L, Olde Damink SW, et al. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int,2011,31:163-175.
[4] Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol,2017,5:142-151.
[5] Manzhalii E, Virchenko O, Falalyeyeva T, et al. Hepatic Encephalopathy Aggravated by Systemic Inflammation. Dig Dis,2019,37:509-517.
[6] Shawcross DL, Wright G, Olde Damink SW, et al. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis,2007,22:125-138.
[7] Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis (Hoboken),2015,5:59-63.
[8] Iebba V, Guerrieri F, Di Gregorio V, et al. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep,2018,8:8210.
[9] Zhang ZG, Zhai HQ, Geng JW, et al. Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing. Am J Gastroenterol,2013,108:1601-1611.
[10] Sung CM, Lin YF, Chen KF, et al. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cell Mol Gastroenterol Hepatol,2019,8:301-318 e2.
[11] Rocco A, Sgamato C, Compare D, et al. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol,2021,9:748253.
[12] Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev,2016:CD003044.
[13] Dhiman RK, Thumburu KK, Verma N, et al. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. Clin Gastroenterol Hepatol,2020,18:800-812 e25.
[14] Fujiwara Y, Suzuki K, Yusa K, et al. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy. Intern Med,2021,60:1027-1033.
[15] Kang DJ, Kakiyama G, Betrapally NS, et al. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clin Transl Gastroenterol,2016,7:e187.
[16] Rahimi RS, Safadi R, Thabut D, et al. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clin Gastroenterol Hepatol,2021,19:2626-2635 e7.
[17] Butterworth RF, Kircheis G, Hilger N, et al. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Exp Hepatol,2018,8:301-313.
[18] Butterworth RF. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis. Metab Brain Dis, 2020,35:75-81.
[19] Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol, 2017,32:1234-1239.
[20] Jain A, Sharma BC, Mahajan B, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology,2022,75:1194-1203. |
